WHO issues MIS-C treatment guidance

Listen
Text
  • Small
  • Medium
  • Large

In a Nov. 23 update, the World Health Organization issued clinical management recommendations for the treatment of multisystem inflammatory syndrome in children, a rare but serious condition tied to COVID-19. 

The recommendations for hospitalized children with MIS-C include: 

  • Use of corticosteroids in addition to supportive care (rather than either intravenous immunoglobulin plus supportive care, or supportive care alone), for hospitalized children aged 0-18 years old who meet a standard case definition for MIS-C.
  • Use of corticosteroids in addition to standard of care for hospitalized children aged 0-18 years who meet both a standard case definition for MIS-C and diagnostic criteria for Kawasaki disease.

The updated guidance is part of the WHO's COVID-19 resource, Clinical management: living guidance, which contains the organization's most up-to-date recommendations for the clinical management of COVID-19 patients.

 

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars